Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.4100
-0.01-2.80%
At close: -
$0.4052
-0.00480-1.17%
After Hours: 5:20 PM EDT
Comments
Loading...
Lyell Immunopharma Analyst Ratings and Price Targets | NASDAQ:LYEL | Benzinga
Lyell Immunopharma Inc has a consensus price target of $2.75 based on the ratings of 5 analysts. The high is $5 issued by JP Morgan on August 28, 2023. The low is $1 issued by HC Wainwright & Co. on April 16, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on April 16, 2025, March 13, 2025, and November 12, 2024, respectively. With an average price target of $1 between HC Wainwright & Co., there's an implied 146.79% upside for Lyell Immunopharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
B of A Securities
JP Morgan
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Lyell Immunopharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/16/2025 | Buy Now | 146.79% | HC Wainwright & Co. | Mitchell Kapoor40% | $1 → $1 | Reiterates | Neutral → Neutral | Get Alert |
| 03/13/2025 | Buy Now | 146.79% | HC Wainwright & Co. | Mitchell Kapoor40% | $1 → $1 | Reiterates | Neutral → Neutral | Get Alert |
| 11/12/2024 | Buy Now | 146.79% | HC Wainwright & Co. | Mitchell Kapoor40% | $1 → $1 | Reiterates | Neutral → Neutral | Get Alert |
| 10/30/2024 | Buy Now | 146.79% | B of A Securities | Geoff Meacham70% | $6 → $1 | Downgrade | Buy → Underperform | Get Alert |
| 10/28/2024 | Buy Now | 146.79% | HC Wainwright & Co. | Mitchell Kapoor40% | $1 → $1 | Reiterates | Neutral → Neutral | Get Alert |
| 08/19/2024 | Buy Now | 146.79% | HC Wainwright & Co. | Mitchell Kapoor40% | $1 → $1 | Reiterates | Neutral → Neutral | Get Alert |
| 06/27/2024 | Buy Now | 1380.75% | B of A Securities | Geoff Meacham70% | $9 → $6 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 146.79% | HC Wainwright & Co. | Mitchell Kapoor40% | $6 → $1 | Downgrade | Buy → Neutral | Get Alert |
| 05/07/2024 | Buy Now | 1380.75% | HC Wainwright & Co. | Mitchell Kapoor40% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 1380.75% | HC Wainwright & Co. | Mitchell Kapoor40% | $8 → $6 | Maintains | Buy | Get Alert |
| 11/09/2023 | Buy Now | 1874.33% | HC Wainwright & Co. | Mitchell Kapoor40% | $9 → $8 | Maintains | Buy | Get Alert |
| 08/28/2023 | Buy Now | 1133.96% | JP Morgan | Eric Joseph41% | $15 → $5 | Downgrade | Overweight → Neutral | Get Alert |
| 05/05/2023 | Buy Now | 2121.13% | HC Wainwright & Co. | Mitchell Kapoor40% | → $9 | Reiterates | → Buy | Get Alert |
| 03/02/2023 | Buy Now | 2121.13% | HC Wainwright & Co. | Mitchell Kapoor40% | $11 → $9 | Maintains | Buy | Get Alert |
| 01/24/2023 | Buy Now | 887.17% | Morgan Stanley | Matthew Harrison54% | $7 → $4 | Maintains | Equal-Weight | Get Alert |
| 11/14/2022 | Buy Now | 1627.54% | Morgan Stanley | Matthew Harrison54% | $15 → $7 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/11/2022 | Buy Now | — | Goldman Sachs | Salveen Richter43% | — | Downgrade | Buy → Neutral | Get Alert |
| 10/17/2022 | Buy Now | 2861.5% | HC Wainwright & Co. | Mitchell Kapoor40% | → $12 | Initiates | → Buy | Get Alert |
| 05/24/2022 | Buy Now | 2861.5% | Goldman Sachs | Salveen Richter43% | $21 → $12 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Lyell Immunopharma (LYEL) stock?
The latest price target for Lyell Immunopharma (NASDAQ:LYEL) was reported by HC Wainwright & Co. on April 16, 2025. The analyst firm set a price target for $1.00 expecting LYEL to rise to within 12 months (a possible 146.79% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lyell Immunopharma (LYEL)?
The latest analyst rating for Lyell Immunopharma (NASDAQ:LYEL) was provided by HC Wainwright & Co., and Lyell Immunopharma reiterated their neutral rating.
When was the last upgrade for Lyell Immunopharma (LYEL)?
There is no last upgrade for Lyell Immunopharma
When was the last downgrade for Lyell Immunopharma (LYEL)?
The last downgrade for Lyell Immunopharma Inc happened on October 30, 2024 when B of A Securities changed their price target from $6 to $1 for Lyell Immunopharma Inc.
When is the next analyst rating going to be posted or updated for Lyell Immunopharma (LYEL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyell Immunopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyell Immunopharma was filed on April 16, 2025 so you should expect the next rating to be made available sometime around April 16, 2026.
Is the Analyst Rating Lyell Immunopharma (LYEL) correct?
While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a reiterated with a price target of $1.00 to $1.00. The current price Lyell Immunopharma (LYEL) is trading at is $0.41, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
